st-271 and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

st-271 has been researched along with Leukemia--Myelogenous--Chronic--BCR-ABL-Positive* in 1 studies

Reviews

1 review(s) available for st-271 and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

Article	Year
[Tyrosine kinase inhibitor--hematological malignancies]. Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:5 STI571 selectively inhibits the ABL-tyrosine kinase, the activity of which is activated by the formation of chimeric BCR/ABL. A phase I study in the USA showed STI571 to be remarkably effective in cases of interferon-refractory chronic myeloid leukemia, with almost no adverse effects. STI571 may become the first choice drug prior to stem cell transplantation and interferon treatment. Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genistein; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein-Tyrosine Kinases; Styrenes; Tretinoin	2001

Article

Year

[Tyrosine kinase inhibitor--hematological malignancies].

Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:5

STI571 selectively inhibits the ABL-tyrosine kinase, the activity of which is activated by the formation of chimeric BCR/ABL. A phase I study in the USA showed STI571 to be remarkably effective in cases of interferon-refractory chronic myeloid leukemia, with almost no adverse effects. STI571 may become the first choice drug prior to stem cell transplantation and interferon treatment.

Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genistein; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein-Tyrosine Kinases; Styrenes; Tretinoin

2001